170 related articles for article (PubMed ID: 36675665)
41. Hepatic venous pressure gradient (HVPG) predicts liver failure after transjugular intrahepatic portal shunt: a retrospective cohort study.
Yao Y; Satapathy SK; Fernandes ESM; Ramírez-Fernández O; Vitale A; Chen Z
Ann Transl Med; 2022 Oct; 10(20):1122. PubMed ID: 36388791
[TBL] [Abstract][Full Text] [Related]
42. The interpretation of hepatic venous pressure gradient tracings - excellent interobserver agreement unrelated to experience.
Tandon P; Ripoll C; Assis D; Wongcharatrawee S; Groszmann RJ; Garcia-Tsao G
Liver Int; 2016 Aug; 36(8):1160-6. PubMed ID: 26763558
[TBL] [Abstract][Full Text] [Related]
43. Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
Sourianarayanane A; Talluri J; Humar A; McCullough AJ
Eur J Gastroenterol Hepatol; 2017 May; 29(5):516-523. PubMed ID: 28079667
[TBL] [Abstract][Full Text] [Related]
44. EUS-guided portal pressure gradient measurement with a novel 25-gauge needle device versus standard transjugular approach: a comparison animal study.
Huang JY; Samarasena JB; Tsujino T; Chang KJ
Gastrointest Endosc; 2016 Aug; 84(2):358-62. PubMed ID: 26945557
[TBL] [Abstract][Full Text] [Related]
45. [The agreement and clinical value of hepatic vein pressure gradient and portal vein pressure in patients with portal hypertension].
Tang S; Qin J; Jiang M; He Q; Yao X; Zeng W; Gu M
Zhonghua Gan Zang Bing Za Zhi; 2015 May; 23(5):354-7. PubMed ID: 26192241
[TBL] [Abstract][Full Text] [Related]
46. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
47. Shear-wave elastography: a noninvasive tool for monitoring changing hepatic venous pressure gradients in patients with cirrhosis.
Choi SY; Jeong WK; Kim Y; Kim J; Kim TY; Sohn JH
Radiology; 2014 Dec; 273(3):917-26. PubMed ID: 25025464
[TBL] [Abstract][Full Text] [Related]
48. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wu F; Yu J; Gan H; Zhang H; Tian D; Zheng D
Sci Rep; 2021 Nov; 11(1):21743. PubMed ID: 34741082
[TBL] [Abstract][Full Text] [Related]
49. Retrorsine Cooperates with Gut Microbiota to Promote Hepatic Sinusoidal Obstruction Syndrome by Disrupting the Gut Barrier.
Xiao L; Hu L; Chu H; Chen L; Yan J; Wang W; Yang X; Zhu Q; Du F; Song Y; Chen P; Hou X; Yang L
J Clin Transl Hepatol; 2022 Dec; 10(6):1086-1098. PubMed ID: 36381109
[TBL] [Abstract][Full Text] [Related]
50. Novel imaging-based approaches for predicting the hepatic venous pressure gradient in a porcine model of liver cirrhosis and portal hypertension.
Ma Y; Dong D; Gong Z; Yan B; Guo Q
Life Sci; 2021 Jan; 264():118710. PubMed ID: 33144188
[TBL] [Abstract][Full Text] [Related]
51. Measurement of intrahepatic pressure as an index of hepatic sinusoidal pressure.
Saito M; Ohnishi K; Terabayashi H; Tanaka H; Iida S; Nomura F
Am J Gastroenterol; 1987 Oct; 82(10):1057-61. PubMed ID: 3661515
[TBL] [Abstract][Full Text] [Related]
52. Wedged hepatic vein portovenography for assessment of Rex vein patency in children with extrahepatic portal venous obstruction.
Kaur P; Khanna R; Sood V; Lal BB; Mukund A; Kilambi R; Alam S
J Pediatr Gastroenterol Nutr; 2024 Jun; ():. PubMed ID: 38847238
[TBL] [Abstract][Full Text] [Related]
53. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ; Ye J; Li X; Li Q; Song YH
World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
[TBL] [Abstract][Full Text] [Related]
54. Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China.
Shang H; Bai T; Zhu S; Yang X; Liu C; Xu D; Zhuge Y; Song Y; Hou X
Ann Transl Med; 2021 Jan; 9(1):11. PubMed ID: 33553304
[TBL] [Abstract][Full Text] [Related]
55. The impact of hepatic steatosis on portal hypertension.
Semmler G; Scheiner B; Schwabl P; Bucsics T; Paternostro R; Chromy D; Stättermayer AF; Trauner M; Mandorfer M; Ferlitsch A; Reiberger T
PLoS One; 2019; 14(11):e0224506. PubMed ID: 31693695
[TBL] [Abstract][Full Text] [Related]
56. Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements.
Steinlauf AF; Garcia-Tsao G; Zakko MF; Dickey K; Gupta T; Groszmann RJ
Hepatology; 1999 Apr; 29(4):1070-3. PubMed ID: 10094948
[TBL] [Abstract][Full Text] [Related]
57. Histological evaluation of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: Correlation with Drum Tower Severity Scoring.
Li R; Li L; Cai Z; Chen J; Zhang H; Zhao S; Tu J; Sun C; Jin Y; Zhang M; Zhang F; Zhang W; Yin Q; Xu H; Han H; Li T; Zhuge Y; Xiao J
Dig Liver Dis; 2024 Jul; 56(7):1220-1228. PubMed ID: 38151450
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi - Case report and literature review.
Tan Y; Zheng S
Open Med (Wars); 2023; 18(1):20230737. PubMed ID: 37333448
[TBL] [Abstract][Full Text] [Related]
59. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
Aramaki T; Sekiyama T; Katsuta Y; Kurokawa H; Komeichi H; Tsutsui H; Terada H; Ohsuga M; Satomura K; Okumura H
J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676
[TBL] [Abstract][Full Text] [Related]
60. Transient Elastography (Fibroscan) in Patients with Non-cirrhotic Portal Fibrosis.
Sharma P; Agarwal R; Dhawan S; Bansal N; Singla V; Kumar A; Arora A
J Clin Exp Hepatol; 2017 Sep; 7(3):230-234. PubMed ID: 28970710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
